NCT05948904 Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study.
| NCT ID | NCT05948904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Condition | Lung Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-11-03 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-11-03 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Developing a standardized methodology for the use of novel cryogenic catheters for transbronchial cryobiopsy and cryoablation of pulmonary lesions.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing lung transplant surgery Exclusion Criteria: * Organ donor ineligible to donate lungs * Healthy individuals
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05948904 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05948904 currently recruiting?
Yes, NCT05948904 is actively recruiting participants. Contact the research team at moishe.liberman@umontreal.ca for enrollment information.
Where is the NCT05948904 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05948904 clinical trial?
NCT05948904 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The trial plans to enroll 200 participants.